Quick Takeaways
- Vensana Capital I GP, LLC filed SCHEDULE 13D for SpyGlass Pharma, Inc. Common Stock, par value $0.00001 per share.
- Disclosed ownership: 9.9%.
- Date of event: 09 Feb 2026.
Vensana Capital I GP, LLC - 09 Feb 2026 SCHEDULE 13D Report for SpyGlass Pharma, Inc. Common Stock, par value $0.00001 per share
- Filing Manager
- Vensana Capital I GP, LLC
- Reporting Manager
- Kirk Nielsen
- Shares outstanding
- 33,455,970 shares
- Disclosed Ownership
- 3,312,141 shares
- Ownership
- 9.9%
- Form type
- SCHEDULE 13D
- Filing time
- 10 Feb 2026, 18:29:55 UTC
- Date of event
- 09 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Vensana Capital I GP, LLC disclosed 9.9% ownership in SpyGlass Pharma, Inc. Common Stock, par value $0.00001 per share on 09 Feb 2026."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 10 Feb 2026, 18:29.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Vensana Capital I GP, LLC | 9.9% | 3,310,619 | 0 | 3,310,619 | /s/ Steven Schwen | Steven Schwen, Chief Financial Officer | 0001854073 |
| Vensana Capital I, L.P. | 9.9% | 3,310,619 | 0 | 3,310,619 | /s/ Steven Schwen | Steven Schwen, Chief Financial Officer of Vensana Capital I GP, LLC, the general partner of Vensana Capital I, L.P. | 0001757539 |
| Kirk Nielsen | 9.9% | 3,312,141 | 1,522 | 3,310,619 | /s/ Steven Schwen | Attorney-in-Fact* | 0001523522 |
| Peter Justin Klein | 9.9% | 3,310,619 | 0 | 3,310,619 | /s/ Steven Schwen | Attorney-in-Fact* | 0001608710 |